This company has been marked as potentially delisted and may not be actively trading. Gemphire Therapeutics (GEMP) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock GEMP vs. TAOX, NNVC, IBIO, MTNB, AEON, OBSV, NRBO, AEZS, NBY, and OGENShould you be buying Gemphire Therapeutics stock or one of its competitors? The main competitors of Gemphire Therapeutics include Synaptogenix (TAOX), NanoViricides (NNVC), iBio (IBIO), Matinas Biopharma (MTNB), AEON Biopharma (AEON), ObsEva (OBSV), NeuroBo Pharmaceuticals (NRBO), Aeterna Zentaris (AEZS), NovaBay Pharmaceuticals (NBY), and Oragenics (OGEN). Gemphire Therapeutics vs. Its Competitors Synaptogenix NanoViricides iBio Matinas Biopharma AEON Biopharma ObsEva NeuroBo Pharmaceuticals Aeterna Zentaris NovaBay Pharmaceuticals Oragenics Synaptogenix (NASDAQ:TAOX) and Gemphire Therapeutics (NASDAQ:GEMP) are both small-cap pharmaceutical preparations industry companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, profitability, earnings, risk, institutional ownership and analyst recommendations. Does the media favor TAOX or GEMP? In the previous week, Synaptogenix had 1 more articles in the media than Gemphire Therapeutics. MarketBeat recorded 1 mentions for Synaptogenix and 0 mentions for Gemphire Therapeutics. Synaptogenix's average media sentiment score of 1.87 beat Gemphire Therapeutics' score of 0.00 indicating that Synaptogenix is being referred to more favorably in the media. Company Overall Sentiment Synaptogenix Very Positive Gemphire Therapeutics Neutral Is TAOX or GEMP more profitable? Synaptogenix's return on equity of -277.76% beat Gemphire Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets SynaptogenixN/A -277.76% -150.79% Gemphire Therapeutics N/A -419.70%-173.05% Do institutionals and insiders hold more shares of TAOX or GEMP? 10.3% of Synaptogenix shares are held by institutional investors. Comparatively, 17.5% of Gemphire Therapeutics shares are held by institutional investors. 2.7% of Synaptogenix shares are held by insiders. Comparatively, 22.7% of Gemphire Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Which has preferable earnings & valuation, TAOX or GEMP? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSynaptogenixN/AN/A-$12.77M-$20.16-0.29Gemphire TherapeuticsN/AN/A-$23.64MN/AN/A Which has more risk and volatility, TAOX or GEMP? Synaptogenix has a beta of 1.87, indicating that its share price is 87% more volatile than the S&P 500. Comparatively, Gemphire Therapeutics has a beta of 2.82, indicating that its share price is 182% more volatile than the S&P 500. SummarySynaptogenix beats Gemphire Therapeutics on 5 of the 8 factors compared between the two stocks. Get Gemphire Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GEMP and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GEMP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GEMP vs. The Competition Export to ExcelMetricGemphire TherapeuticsPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$9.43M$887.58M$5.75B$9.76BDividend YieldN/A4.84%4.10%4.04%P/E RatioN/A1.1083.2726.59Price / SalesN/A26.93535.03111.31Price / CashN/A19.5637.4459.26Price / Book1.176.5510.556.58Net Income-$23.64M-$5.07M$3.27B$265.95M Gemphire Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GEMPGemphire TherapeuticsN/A$0.63-2.0%N/A-82.8%$9.43MN/A0.009Gap DownTAOXSynaptogenixN/A$6.96-0.7%N/AN/A$24.44MN/A-0.354Positive NewsNNVCNanoViricides0.3956 of 5 stars$1.43-3.4%N/A-28.7%$22.98MN/A-1.9920IBIOiBio1.8774 of 5 stars$0.79-6.9%$5.00+535.2%-58.5%$15.47M$375K0.00100Positive NewsAnalyst RevisionHigh Trading VolumeMTNBMatinas Biopharma0.5846 of 5 stars$2.10-2.3%N/AN/A$10.68MN/A-0.4330AEONAEON Biopharma2.911 of 5 stars$0.76+4.3%$360.00+47,493.9%-98.8%$8.81MN/A4.205Gap UpOBSVObsEvaN/AN/AN/AN/A$7.94MN/A0.0050News CoverageNRBONeuroBo PharmaceuticalsN/A$0.650.0%N/A-82.8%$5.60MN/A0.0010AEZSAeterna ZentarisN/A$2.93-10.9%N/A-24.2%$5.25M$2.37M-0.2020High Trading VolumeNBYNovaBay Pharmaceuticals0.7247 of 5 stars$0.90-0.8%$0.85-5.5%+265.7%$5.24M$9.78M-0.0230Gap UpHigh Trading VolumeOGENOragenics0.113 of 5 stars$1.12flatN/A-97.2%$4.62MN/A-0.165 Related Companies and Tools Related Companies Synaptogenix Competitors NanoViricides Competitors iBio Competitors Matinas Biopharma Competitors AEON Biopharma Competitors ObsEva Competitors NeuroBo Pharmaceuticals Competitors Aeterna Zentaris Competitors NovaBay Pharmaceuticals Competitors Oragenics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GEMP) was last updated on 8/31/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gemphire Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Gemphire Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
